Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Sequencing › Ovarian Cancer Mutational Signatures, Immune Features Tied to Combination Treatment Response

Ovarian Cancer Mutational Signatures, Immune Features Tied to Combination Treatment Response

Mar 19, 2020
|
staff reporter

NEW YORK – A new genomic, immune profiling, and imaging study suggests there may multiple signatures for predicting response to a PARP inhibitor and checkpoint immunotherapy drug combination in advanced ovarian cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

What's Popular?

In Sequencing

  1. Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk

  2. T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma

  3. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.